Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2004 Dec 31;27953:55147-52. doi: 10.1074/jbc.M410826200.
Show Gene links
Show Anatomy links
A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.
Hertel J
,
Struthers H
,
Horj CB
,
Hruz PW
.
???displayArticle.abstract???
Human immunodeficiency virus (HIV) protease inhibitors (PIs) act as reversible noncompetitive inhibitors of GLUT4 with binding affinities in the low micromolar range and are known to contribute to alterations in glucose homeostasis during treatment of HIV infection. As aspartyl protease inhibitors, these compounds all possess a core peptidomimetic structure together with flanking hydrophobic moieties. To determine the molecular basis for GLUT4 inhibition, a family of related oligopeptides containing structural elements found in PIs was screened for their ability to inhibit 2-deoxyglucose transport in primary rat adipocytes. The peptide oxybenzylcarbonyl-His-Phe-Phe-O-ethyl ester (zHFFe) was identified as a potent inhibitor of zero-trans glucose flux with a K(i) of 26 mum. Similar to PIs, transport inhibition by this peptide was acute, noncompetitive, and reversible. Within a Xenopus oocyte expression system, zHFFe acutely and reversibly inhibited GLUT4-mediated glucose uptake, whereas GLUT1 activity was unaffected at concentrations as high as 1 mm. The related photoactivatable peptide zHFF-p-benzoylphenylalanine-[(125)I]Tyr-O-ethyl ester selectively labeled GLUT4 in rat adipocytes and indinavir effectively protected against photolabeling. Furthermore, GLUT4 bound to a peptide affinity column containing the zHFF sequence and was eluted by indinavir. These data establish a structural basis for PI effects on GLUT4 activity and support the direct binding of PIs to the transport protein as the mechanism for acute inhibition of insulin-stimulated glucose uptake.
Aiello,
Dipeptide metalloendoprotease substrates are glucose transport inhibitors and membrane structure perturbants.
1986, Pubmed
Aiello,
Dipeptide metalloendoprotease substrates are glucose transport inhibitors and membrane structure perturbants.
1986,
Pubmed
Cammalleri,
The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling.
2003,
Pubmed
Caron,
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.
2001,
Pubmed
Carr,
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
1998,
Pubmed
Holman,
Cell surface labeling of glucose transporter isoform GLUT4 by bis-mannose photolabel. Correlation with stimulation of glucose transport in rat adipose cells by insulin and phorbol ester.
1990,
Pubmed
Hruz,
Indinavir induces acute and reversible peripheral insulin resistance in rats.
2002,
Pubmed
Inouye,
New synthetic substrates for pepsin.
1966,
Pubmed
Keller,
Functional expression of the human HepG2 and rat adipocyte glucose transporters in Xenopus oocytes. Comparison of kinetic parameters.
1989,
Pubmed
,
Xenbase
Koster,
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
2003,
Pubmed
Mulligan,
Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.
2000,
Pubmed
Murata,
Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations.
2002,
Pubmed
,
Xenbase
Murata,
The mechanism of insulin resistance caused by HIV protease inhibitor therapy.
2000,
Pubmed
,
Xenbase
Noor,
Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.
2002,
Pubmed
Palella,
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
1998,
Pubmed
Schütt,
The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells.
2000,
Pubmed
Schwarcz,
Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996.
2000,
Pubmed
Smith,
Immunoelectron microscopic demonstration of insulin-stimulated translocation of glucose transporters to the plasma membrane of isolated rat adipocytes and masking of the carboxyl-terminal epitope of intracellular GLUT4.
1991,
Pubmed
Wang,
Insulin unmasks a COOH-terminal Glut4 epitope and increases glucose transport across T-tubules in skeletal muscle.
1996,
Pubmed
Woerle,
Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.
2003,
Pubmed
Xu,
Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
2004,
Pubmed
